rofecoxib has been researched along with Adenoma, Basal Cell in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas." | 9.12 | A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. ( Baron, JA; Bolognese, JA; Bresalier, RS; Horgan, K; Lanas, A; Loftus, S; Morton, DG; Oxenius, B; Quan, H; Riddell, R; Sandler, RS, 2006) |
| " We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer." | 9.12 | Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007) |
| " We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas." | 5.12 | A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. ( Baron, JA; Bolognese, JA; Bresalier, RS; Horgan, K; Lanas, A; Loftus, S; Morton, DG; Oxenius, B; Quan, H; Riddell, R; Sandler, RS, 2006) |
| " We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer." | 5.12 | Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007) |
| "Most colorectal cancers are believed to develop from colorectal adenomas." | 1.32 | The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. ( Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rahme, E | 1 |
| Barkun, AN | 1 |
| Toubouti, Y | 1 |
| Bardou, M | 1 |
| Senior, K | 1 |
| Noguera Aguilar, JF | 1 |
| Amengual Antich, I | 1 |
| Morón Canis, JM | 1 |
| Plaza Martínez, A | 1 |
| Martínez Córcoles, JA | 1 |
| Tortajada Collado, C | 1 |
| Pujol Tugores, JJ | 1 |
| Lee, YH | 1 |
| Ji, JD | 1 |
| Song, GG | 1 |
| Baron, JA | 1 |
| Sandler, RS | 1 |
| Bresalier, RS | 1 |
| Quan, H | 1 |
| Riddell, R | 1 |
| Lanas, A | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Loftus, S | 1 |
| Morton, DG | 1 |
| Lynch, PM | 1 |
| Kerr, DJ | 1 |
| Dunn, JA | 1 |
| Langman, MJ | 1 |
| Smith, JL | 1 |
| Midgley, RS | 1 |
| Stanley, A | 1 |
| Stokes, JC | 1 |
| Julier, P | 1 |
| Iveson, C | 1 |
| Duvvuri, R | 1 |
| McConkey, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204] | Phase 3 | 1,620 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Phase III, Randomized, Double Blind, Placebo Controlled Study of Rofecoxib in Colorectal Cancer Patients Following Adjuvant Chemotherapy[NCT00031863] | Phase 3 | 0 participants | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for rofecoxib and Adenoma, Basal Cell
| Article | Year |
|---|---|
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactone | 2007 |
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cycloox | 2006 |
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cycloox | 2006 |
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cycloox | 2006 |
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cycloox | 2006 |
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Topics: Adenoma; Aged; Cardiovascular Diseases; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclooxygenase | 2007 |
4 other studies available for rofecoxib and Adenoma, Basal Cell
| Article | Year |
|---|---|
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cel | 2003 |
COX-2 inhibitors: cancer prevention or cardiovascular risk?
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Topics: Adenocarcinoma; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Car | 2005 |
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Topics: Adenoma; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; | 2006 |